Mohammad AskarPublic working copy · medical review pending

Posterior uveitis · 033

Posterior uveitis: distinguish Behçet, VKH and sarcoidosis

Localize the inflammation, identify infection and assess threatened vision before choosing immunosuppression. Behçet predominantly causes occlusive retinal inflammation, VKH choroiditis, and sarcoidosis variable granulomatous disease; their patterns overlap.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Use clinical course, systemic findings and multimodal imaging together. Treat sight-threatening inflammation promptly, while distinguishing a source protocol or selected study result from a universal treatment rule.

Terminology and draft status

Terminology review is not complete. Four actually inspected WHO UMD entries are recorded in terminology.md; they do not approve the entire translation.

01Establish the inflammatory pattern and infection risk

Posterior uveitis, panuveitis and retinal vasculitis describe the site and distribution of inflammation, not its cause. Assess acuity, intraocular pressure, anterior chamber, vitreous, retina and choroid; document macular oedema, ischaemia and optic-disc involvement. 11

Before immunosuppression, investigate infectious mimics, particularly syphilis and tuberculosis (TB). Quantiferon is an interferon-gamma release assay (IGRA); a negative result alone excludes neither active nor ocular TB, and latent infection must be distinguished from active disease. 11 12

Blood count, liver and kidney function and inflammatory markers such as ESR/CRP support evaluation and treatment safety. Testing is guided by phenotype and risk; “VKH needs no laboratory tests” must not be interpreted as permission to omit differential diagnosis or baseline safety assessment. 11 12

Optical coherence tomography (OCT) shows fluid and tissue structure; fluorescein angiography (FA) assesses leakage and perfusion. Indocyanine green angiography (ICGA, originally ICG) adds choroidal information; an imaging pattern complements, rather than replaces, clinical assessment. 5 11

02Recognize Behçet without relying on one marker

Behçet disease is a relapsing systemic vasculitis affecting arteries and veins of different sizes. Recurrent oral/genital ulcers, skin lesions and ocular inflammation should trigger a coordinated ophthalmic and rheumatological assessment. 1 2

Original teaching case 1: a 50-year-old man has bilateral floaters, reduced vision and retinal lesions, with oral and leg lesions. This combination raises suspicion of Behçet but is not a confirmed diagnosis; examine the lesions and exclude infectious or other inflammatory causes. 16

The usual ocular phenotype is nongranulomatous uveitis, often bilateral panuveitis with diffuse smoky vitritis and superficial white retinal infiltrates. A mobile, relatively fibrin-poor hypopyon contains inflammatory cells and is not itself proof of bacterial pus; large mutton-fat keratic precipitates (KPs) prompt reconsideration of the differential. The original contrast with vitreous snowballs is descriptive, not an exclusion criterion. 2 16

Occlusive retinal vasculitis can produce venous obstruction, diffuse capillary leakage and permanent visual damage. Clinical sheathing or a frosted-branch appearance is not the same as the angiographic pattern; the original claims of universally silent FA, scar-free retinitis and the globally commonest cause of inflammatory vein occlusion are not accepted as rules. Retinal location alone does not establish absence of retinal pigment epithelium (RPE)/choroidal involvement or angiographic activity. 2 16

The original figures 80–95% bilateral disease and oral ulcers>98%, skin lesions 90%, genital ulcers 73% and ocular involvement 70% are population-dependent and not independently validated here. Neurological events, cranial-nerve signs, epididymitis, arthritis, gastrointestinal disease, aortic disease and recurrent deep-vein thrombosis remain important systemic clues. 16

HLA-B51 supports susceptibility but neither confirms nor excludes Behçet. The original 50–60% association, nearly 100% HLA-A29 in birdshot and 92% HLA-B27 in spondylitis must not be treated as interchangeable diagnostic sensitivities; their populations and denominators remain unresolved. 1 16

Pathergy is an exaggerated reaction after sterile needle injury, sometimes forming a pustule. Contrary to the original statement, the International Criteria for Behçet Disease (ICBD) retain an optional 1 point for a positive test; a negative result does not exclude Behçet, and criteria sets must be named. 1

ICBD validation reported 94.8% sensitivity and 90.5% specificity in a selected multinational clinical/control dataset. These are classification-performance results, not a stand-alone probability for this patient; Standardization of Uveitis Nomenclature (SUN) research criteria use their own defined framework. 1 2

03Suppress Behçet inflammation and monitor response

For sight-threatening posterior Behçet inflammation, rapidly suppress activity and prevent relapses. EULAR 2025 update, published 2026, recommends immunosuppressive treatment and rejects glucocorticoid monotherapy; steroids can provide rapid induction alongside appropriate immunomodulation. 3

Azathioprine (Imuran) and cyclosporine are conventional options; the export also mentions mycophenolate mofetil (MMF). Colchicine can help mucocutaneous/joint manifestations but does not substitute for effective treatment of sight-threatening posterior disease. 3 16

Monoclonal anti-TNF-α agents block a pro-inflammatory cytokine. Infliximab is a chimeric antibody given intravenously; adalimumab is a human, rather than “fully humanized”, monoclonal antibody given subcutaneously. 3 15

EULAR favours early monoclonal anti-TNF treatment for sight-threatening posterior involvement, preferably infliximab with another immunosuppressive agent. Possible reduction in immunogenicity does not guarantee prevention of neutralizing antibodies, autoimmune adverse effects or loss of response. 3 4

The 2026 supporting review found heterogeneous ocular studies and could not pool them; comparative studies of adding conventional agents to biologics gave conflicting results. The export’s assertion of infliximab failure after 1 year without combination treatment is not a reliable universal prognosis. 4 16

The original speaker-practice claim of anti-TNF within 48 hours after TB/syphilis screening, with an antimetabolite but no systemic steroid, is not a general protocol. Urgency is real, but infection assessment, induction treatment, comorbidities and monitoring require specialist decisions. 3 16

Interferon-alpha-2a remains an alternative mentioned in the lecture and studied in Behçet; flu-like symptoms are relevant adverse effects. Availability and individual tolerability matter; retinal/macular atrophy, macular hole and optic atrophy may limit recovery despite control of inflammation. 4 16

04Identify VKH choroiditis and its stage

Vogt–Koyanagi–Harada (VKH) disease is associated with an immune response against melanocyte-related antigens in the uvea, inner ear, meninges and skin. Stromal choroiditis can lead secondarily to exudative retinal detachment (ERD). 5

Original teaching case 2: a 25-year-old woman presents with headache, tinnitus, bilateral reduced vision, ERD and disc hyperaemia. Look for choroiditis and neurological/auditory features, while excluding mimics; this illustrative presentation is not a diagnostic test. 5 16

OCT may show septated subretinal fluid and undulating retinal pigment epithelium (RPE). FA may show disc staining/leakage and multiple pinpoint leaks with late pooling, described as a starry-sky pattern; timing and prior treatment affect the findings. 5 17

ICGA may reveal hypofluorescent dark dots and otherwise subclinical involvement of the fellow eye. These are imaging signs compatible with stromal inflammation, not direct histological proof that each dot is a granuloma; no single test establishes the full diagnosis. 5

The original 98% ICG protein-binding figure is retained as an unverified exact value here; the current product text confirms strong plasma-protein binding. Enhanced-depth imaging OCT (EDI-OCT) measures the choroid, but original thresholds>300 µm and often>500–800 µm are not universal diagnostic cutoffs. 14 16

The prodrome can include flu-like illness, headache, tinnitus and hearing loss. The acute uveitic phase features choroiditis, disc hyperaemia and ERD, sometimes with little anterior activity; convalescence may bring vitiligo/poliosis, and chronic recurrence can cause granulomatous anterior uveitis, sunset-glow depigmentation and choroidal atrophy. 5

VKH is characteristically bilateral, with unequal or subclinical involvement possible. The original age around 30 years, slight female predominance and higher frequency in more pigmented populations are descriptive associations, not exclusion rules; neither a normal single thickness reading nor absent anterior inflammation settles the diagnosis. 5 16

Sunset-glow fundus reflects RPE/choroidal depigmentation in chronic disease; the original Sugiura-sign attribution alongside skin/hair changes remains terminologically unresolved. Sympathetic ophthalmia is a separate, overlapping differential after penetrating trauma or intraocular surgery, not simply “traumatic VKH”. 5 16

05Treat VKH early without promising cure

Treat active VKH promptly to reduce recurrence and structural damage. A precisely proven few-day deadline, inevitable cure, or sunset glow as proof of clinician delay is not established by the reviewed evidence. Complications include cataract, glaucoma and choroidal neovascularization (CNV), meaning new choroidal vessels. 6 7

The original adult teaching regimen describes methylprednisolone 1 g intravenously for 3–5 days with MMF 1 g twice daily, then oral prednisolone 1 mg/kg. These source doses are not individualized prescribing instructions; severe disease, infection risk and organ function require specialist assessment. The export includes inpatient admission; admission depends on severity and the ability to investigate and monitor safely. 16 17

The same export describes tapering steroids over about 4 months, full-dose MMF for at least 8 months and about 16 months overall. These are source-specific durations, not a validated schedule for every patient; taper according to sustained control and safety rather than a fixed calendar. 6 16

In the prospective uncontrolled MMF-plus-steroid series,38 patients/76 eyes were followed for a mean 37 months. No sunset-glow fundus was reported, but glaucoma occurred in 2 eyes and cataract in 5 eyes; this directly contradicts a general 0% complication guarantee and does not prove permanent cure. 6

The FAST VKH subgroup randomized 93 patients;85 contributed to the primary endpoint. At 6 months, corticosteroid-sparing control was 80.4% with methotrexate (MTX) versus 64.1% with MMF, with abstract P=.12; nonsignificance does not demonstrate equivalence, and subgroup size/missing outcomes limit inference. 7

FAST also reported greater anatomical improvement with MTX for central thickness and serous-detachment resolution, without a significant difference in visual-acuity improvement. Anatomical change and vision are different outcomes; indexed statistical/registry inconsistencies need reconciliation before stronger claims. 7

Children may present late, but the statement that childhood VKH is never more aggressive is unverified. MTX is a specialist option rather than an automatic age-based choice; follow inflammation, growth, dose suitability and systemic toxicity. 16

Pregnancy requires coordinated ophthalmic, obstetric and medical care. The export mentions steroid pulses and cyclosporine, but MMF is teratogenic and is not a pregnancy substitute; the transplant-label exception does not authorize VKH use in pregnancy. ICG is not universally contraindicated: the applicable UK label calls for caution under limited data, not proof of safety. 13 14 16

06Investigate suspected ocular sarcoidosis

Sarcoidosis is a multisystem granulomatous disease and a great mimicker of uveitis. It may be unilateral or bilateral and affect anterior, intermediate or posterior tissues; compatible ocular findings alone do not prove systemic sarcoidosis. The clinical appearance can also be nongranulomatous. 8

Look for mutton-fat KPs, iris nodules, broad posterior synechiae and angle nodules, called Berlin nodules in the export. Nodular or segmental retinal periphlebitis can resemble candle-wax drippings; similar venous patterns also occur with TB or multiple sclerosis. FA may show segmental/multifocal venous leakage; this contrast with diffuse leakage is not an absolute diagnostic rule. 8 16

Choroidal nodules can resemble VKH, and optic-disc swelling or granulomas may accompany inflammation. Disc swelling is not specific, and neither the presence of marked anterior inflammation nor absence of ERD makes the differential absolute. 8 9

Exclude alternative granulomatous causes, particularly TB and syphilis. The original paired Quantiferon/PPD recommendation is not a universal rule; a 0 mm tuberculin skin reaction may reflect anergy and does not exclude TB. The explanation that macrophages are merely “busy” is not an adequate immune mechanism. 8 11 16

Serum angiotensin-converting enzyme (ACE) and lysozyme are supportive tests with limited specificity and sensitivity; normal results do not exclude disease and age affects interpretation. Chest CT can reveal disease missed on radiography, but radiation, pretest probability and clinical context guide selection. The original age pattern of often-normal adult and physiologically higher childhood values needs age-appropriate reference ranges. 8 12

Histology seeks noncaseating/nonnecrotizing granulomas, not “noncalcifying” granulomas; exclude infection and other granulomatous causes. The revised International Workshop on Ocular Sarcoidosis (IWOS) framework distinguishes biopsy-supported and clinically supported categories, so a biopsy is not required for every classification category. 8

Conjunctival biopsy yield is not universally zero when the surface looks unremarkable. A historical prospective study reported positive biopsies in 33% of 60 confirmed sarcoidosis patients, without a predictive relation to slit-lamp findings; this does not justify random biopsy for everyone, and site selection and processing affect yield. 10

07Choose sarcoidosis treatment by activity and location

Treat according to inflammatory activity, vision threat, location and systemic involvement. Topical corticosteroids may suffice for selected anterior disease; posterior or panuveitic activity needs assessment of local and/or systemic options, rather than automatically using one regimen. 9

IWOS lists MTX, azathioprine, MMF and cyclosporine as steroid-sparing options without establishing universal MMF superiority. The original preferences for MTX in children and cyclosporine in pregnancy require individual indication, monitoring and safety review. 9 13 16

Adalimumab and infliximab may be considered in selected refractory disease; rituximab targets CD20 but is a specialist rescue option with limited disease-specific evidence. A drug’s use in a small series or another disease does not establish a routine sarcoidosis indication. 9 16

IWOS treatment guidance derives from an international expert survey and consensus, not a comparative trial proving the best drug. Excluding infection remains central, but diagnosis also establishes systemic extent, complications and follow-up; it is not merely a preliminary screen before generic immunosuppression. 9

08Compare patterns while retaining uncertainty

The table retains every original comparison row while replacing absolute diagnostic and treatment rules with clinical clues. Assess activity and damage separately; atypical findings should reopen the differential. 1 5 8

Follow visual function, inflammatory activity and treatment toxicity together. Recurrent symptoms, new neurological features or deteriorating vision warrant reassessment; improvement on steroids alone does not establish a noninfectious cause. 11 12

Compare patterns while retaining uncertainty
FeatureBehçet diseaseVogt–Koyanagi–Harada (VKH)Sarcoidosis
PathophysiologySystemic variable-vessel vasculitis.Melanocyte-associated immune disease; primary choroiditis.Multisystem granulomatous disease.
Usual uveitis patternOften bilateral nongranulomatous panuveitis.Bilateral choroiditis; recurrent disease can become granulomatous anterior uveitis.Variable laterality and anterior/intermediate/posterior/panuveitic involvement.
Ocular cluesMobile relatively fibrin-poor hypopyon, retinal vasculitis and infiltrates; permanent damage can occur.Serous retinal detachment, disc hyperaemia and later sunset glow.Mutton-fat KPs, iris/angle nodules, candle-wax periphlebitis and disc changes.
Systemic cluesOral/genital ulcers, skin lesions and thromboses.Headache, tinnitus/hearing symptoms and skin/hair depigmentation.Pulmonary, cutaneous and neurological involvement.
Diagnostic approachClinical phenotype, differential diagnosis and infection evaluation; HLA-B51 is supportive.Clinical pattern plus OCT/FA/ICGA; choroidal thickening is context-dependent.Exclude mimics; chest imaging, supportive tests and selected biopsy/IWOS category.
Treatment principlesPrompt immunosuppression, early anti-TNF in sight threat; avoid steroid monotherapy.Prompt systemic anti-inflammatory/steroid-sparing treatment; no guaranteed cure or fixed universal deadline.Activity-guided local/systemic treatment; MTX/MMF/other agents or selected biologics.
Important limitsNo universal scar-free course or global frequency ranking.Unequal/subclinical bilateral involvement; thickness is not a stand-alone test; sympathetic ophthalmia is distinct.Anergy and normal laboratory tests do not settle TB exclusion or sarcoidosis diagnosis.
What are the main learning points of this posterior-uveitis lecture?

Use clinical course, systemic findings and multimodal imaging together. Treat sight-threatening inflammation promptly, while distinguishing a source protocol or selected study result from a universal treatment rule.

Which findings require urgent assessment?

Sudden vision loss, severe pain, a new field defect, marked inflammation, pressure-related symptoms or suspected infection/neurological disease require urgent assessment. Do not wait for routine imaging when vision is acutely threatened.

References and access status

  1. 1
    ICBD multinational criteria study

    Complete actual NCBI abstract read; main report and study-level validation details unread.

  2. 2
    SUN classification: Behçet disease uveitis

    Complete actual indexed abstract read; direct PMC main page returned CAPTCHA. Research classification, not a stand-alone bedside diagnostic test.

  3. 3
    EULAR Behçet recommendations:2025 update, published2026

    Complete NCBI abstract and indexed eye recommendation text read; direct publisher/DOI full-text access returned403. No whole-guideline appraisal claimed.

  4. 4
    EULAR2026 major-organ systematic literature review

    Actual Europe PMC XML introduction, methods, selected results/eye systemic-treatment text and tables read. Supplement/protocol/underlying trials unread.

  5. 5
    SUN classification: Vogt–Koyanagi–Harada disease

    Complete NCBI abstract and indexed Tables3–4/choroidal-imaging discussion read. Full XML retrieval failed; figures and underlying studies not appraised.

  6. 6
    Abu El-Asrar et al. MMF plus corticosteroids in initial VKH

    Complete actual abstract and selected original PDF methods/results/complication text read via author-university copy, DOI10.1111/aos.13189. Figures/supplements not appraised.

  7. 7
    FAST VKH subgroup outcomes2024

    Complete actual NCBI abstract read; indexed main-text extracts reveal statistical/registry discrepancies. Full report, protocol, supplement and registry reconciliation pending.

  8. 8
    Revised IWOS diagnostic criteria2019

    Complete actual NCBI abstract read; direct publisher main page403. Consensus categories, not independently validated by this review.

  9. 9
    IWOS management recommendations2021

    Complete NCBI abstract and actual PDF selected methods, anterior/posterior-treatment text, Boxes1–4 and discussion read via GMIO-hosted article copy; official PDF returned non-PDF. Supplement unread.

  10. 10
    Conjunctival biopsy in sarcoidosis1977

    Complete NCBI abstract read; historical prospective study, main text/normal-conjunctiva subgroup details unread.

  11. 11
    DOG/BVA diagnostic quick guide, actual footer10/2022

    Actual entire one-page diagnostic text read. Filename2025 differs from footer10/2022; do not infer a new2025 evidence review.

  12. 12
    DOG/BVA24b posterior noninfectious uveitis, August2017

    Actual selected section3.3/urgent diagnostic text printed pp7–8 read. Historical guideline, not the entire33pages or current disease-specific recommendation appraisal.

  13. 13
    EMA CellCept product information

    Actual current PDF selected4.3 and teratogenic-warning text in4.4 read; EMA catalog updated7May2026. Transplant label, not VKH authorization or a full prescribing review.

  14. 14
    UK Zyogreen SmPC,25September2026

    Actual selected4.1,4.3–4.6 and5.2 text read; product/jurisdiction-specific. No German approval or universal pregnancy safety claim.

  15. 15
    EMA Humira: human monoclonal antibody

    Actual indexed leaflet extract on human antibody/TNF target read; direct catalog429. No complete current SmPC, monitoring or local authorization review claimed.

  16. 16
    Original posterior-uveitis exported lecture

    Complete local original lecture/wrapper read. Video/transcript/speaker attribution unverified; original numeric protocols are not independent clinical evidence.

  17. 17
    AAO Uveitis Subspecialty Day2024, VKH teaching case

    Indexed actual teaching text printed p42 read; full PDF, images and cited studies not appraised. Educational case, not a new practice guideline.

Original lecture link